In a study published in the journal Immunology, Southampton University researchers have shown that a new antibody that they have engineered is able to combine two different anticancer approaches: depleting regulatory T cells and activating killer T cells [1]. Abstract The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies…

Researchers at the University of Notre Dame discovered that amino acid nitration can inhibit the activation of T cells employed in immunotherapy against cancer and that suppression of reactive nitrogen species (RNS) responsible for nitration can significantly boost the effectiveness of immunotherapy [1]. Abstract Potent immunosuppressive mechanisms within the tumor microenvironment contribute to the resistance…

Scientists at the MRC Cancer Unit of the Wellcome Sanger Institute and other departments of the University of Cambridge discovered that healthy esophageal tissue accumulates very high numbers of mutations with age, to the point that, by the time middle age is reached, it is likely to contain more cells with a particular mutation than…

Cancer is the poster child of age-related diseases, and a recent study sheds light on why the risk of cancer rises dramatically as we age. Abstract For many cancer types, incidence rises rapidly with age as an apparent power law, supporting the idea that cancer is caused by a gradual accumulation of genetic mutations. Similarly,…

Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights. Dr. James Peyer is the founder and Managing Partner…

Researchers at the Imperial College London have discovered that specifically employing invariant natural killer T cells, rather than generic T cells, in cancer immunotherapies based on chimeric antigen receptors might lead to significantly more effective, cheaper, and more easily mass-produced treatments [1]. Abstract Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19+ B…

Led by Dr. Alicja Copik, scientists at the University of Central Florida College of Medicine have discovered that it might be possible to make cancer immunotherapy work for a larger portion of patients by employing PM21-activated natural killer (PM21-NK) cells [1]. Study abstract Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited…

Today, we would like to share a talk given by Stephen Hilbert, President of Oisin Biotechnologies, in which he discusses treating aging and cancer by removing harmful senescent cells. On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part…

Researchers from the Walter and Eliza Hall Institute, the Monash Institute of Pharmaceutical Sciences, and Cancer Therapeutics CRC have developed a new type of drug that harnesses cellular senescence as a weapon against cancer [1]. Study abstract Acetylation of histones by lysine acetyltransferases (KATs) is essential for chromatin organization and function. Among the genes coding…

Researchers at the Rockefeller University have clarified the mechanism by which certain types of breast cancer become immune to specific drugs designed to eliminate them. More specifically, they figured out how the loss of the protein 53BP1 due to BRCA1 mutation allows cancers to become insensitive to PARP inhibitors [1]. Study summary In DNA repair,…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD